SRP8053
IL-35 (mouse): FC (human)
recombinant, expressed in CHO cells
Synonym(s):
Interleukin-35, T-cell immunoglobulin and mucin domain-containing protein 4
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352200
NACRES:
NA.32
Recommended Products
biological source
human
mouse
recombinant
expressed in CHO cells
Assay
≥98% (SDS-PAGE)
form
lyophilized
mol wt
monomer 23 kDa by calculation (IL-12a (p35))
monomer 46 kDa by calculation (Ebi3)
packaging
pkg of 5 μg
technique(s)
activity assay: suitable
impurities
<0.06 EU/μg endotoxin, tested
color
white
shipped in
wet ice
storage temp.
−20°C
Gene Information
mouse ... Ebi3(50498) , Il12a(16159)
General description
Research area: IMMUNO AND CKS. Interleukin-35 (IL-35) is a novel IL-12 family cytokine produced by regulatory T cells (Treg) but not by resting or activated effector T cells (Teff). IL-35 is a heterodimeric protein composed of EBI3 (Epstein-Barr-Virus-induced gene 3) and IL-12a (p35). EBI3 is a downstream target of Foxp3, a transcription factor required for Treg-cell development and function, and thus Treg-cell restriction of IL35 occurs.
Application
IL-35 has been used to study its immunosuppressive effect on acute graft-versus-host disease in a mouse model.Ithas also been used to study its effects on the differentiation of granulocytemacrophage-colony-stimulating factor-producing T helper cells (ThGM). IL-35has been used to study its effects on bleomycin-induced pulmonary fibrosis.
Biochem/physiol Actions
Regulatory T cells are essential for maintaining self tolerance and preventing autoimmunity, and IL-35 is identified as a molecule that mediates the immune suppression function of Treg-cell. As an inhibitory cytokine, IL-35 induces proliferation of Treg-cell populations but suppresses Th17 cell development. Studies in mice show the absence of either IL-35 chain from Treg-cell reduces the cells′ ability to suppress inflammation using an experimental model for inflammatory bowel disease. IL-35 is suggested as a potential target of immunotherapy.IL-35 is produced inresponse to agonists of toll-like receptors 3 and 4 (TLR 3 & 4) and interferon γ (IFN-γ). It is secreted mainly by activated B cells, CD4+ Foxp3+ regulatoryT cells (Tregs), and at a lower concentration by monocytes, smooth muscle cells, and endothelial cells.
Physical form
Lyophilized from 0.2 μm-filtered solution in PBS.
Reconstitution
Reconstitute at 100 μg/mL in sterile PBS.
Other Notes
The mouse IL-35 complex composed of the Ebi3 subunit (aa 23-228) and the IL-12a (p35) subunit (aa 23-215) is fused through a polypeptide linker to the Fc region of human IgG1.
Storage Class Code
10 - Combustible liquids
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Fengqin Lin et al.
Molecular immunology, 164, 28-38 (2023-11-09)
The immune system contributes to the pathophysiology of endometriosis. The role of ThGM cells, which produce granulocyte macrophage-colony-stimulating factor (GM-CSF), in the pathogenesis of endometriosis remains unknown. To analyze the features of ThGM cells in endometriosis, a mouse endometriosis model
IL-35 inhibits acute graft-versus-host disease in a mouse model
Zhang X H, et al.
International Immunopharmacology, 29(2), 383-392 (2015)
The inhibitory cytokine IL-35 contributes to regulatory T-cell function.
Collison LW
Nature, 450, 566-569 (2007)
Jinjung Choi et al.
Clinical reviews in allergy & immunology, 49(3), 327-332 (2015-01-27)
Interleukin 35 (IL-35) is the most recently identified member of the IL-12 family of cytokines and offers the potential to be a target for new therapies for autoimmune, inflammatory, and infectious diseases. Similar to other members of the IL-12 family
IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells.
Niedbala W
European Journal of Immunology, 37, 3021-3029 (2007)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service